the $11 BILLION company Sarepta targets only 13% of DMD patients with their drug eteplirsen , our Antisense targets 100% of all DMD patients . The most people still didnt really realize the full monster potential here this one could be a pure goldmine .
Could Antisense be the next multi-billion Duchenne Muscular Dystrophy biotech?
https://unauthorised investment advice/health/could-antisense-be-the-next-multi-billion-duchenne-muscular-dystrophy-biotech/
“I joined the board of Sarepta in 2007. We were in a very similar circumstance as Antisense,” he told *.“We had a low market cap, we had low cash balance, we were fighting to get to the point where we could prove out our drug. Now look at what’s changed in the last 10 years. That’s what we’re trying to achieve at Antisense.”
the $11 BILLION company Sarepta targets only 13% of DMD patients...
-
- There are more pages in this discussion • 183 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
8.9¢ |
Change
-0.046(34.1%) |
Mkt cap ! $80.23M | |||
| Open | High | Low | Value | Volume |
| 8.7¢ | 9.0¢ | 8.6¢ | $2.082M | 23.82M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 250808 | 8.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.9¢ | 312804 | 3 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| PER (ASX) Chart |